Genmab A/S (GMAB)

About Genmab A/S

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

As of November 3, 2026, Genmab A/S (GMAB) stock rose to $55.51, up 1.07% (+$0.59) versus the previous close. On the day, shares have traded between $55.10 and $56.50. That puts GMAB in the upper third of its 52-week range of $23.62 to $59.97. Genmab A/S carries a market capitalization of roughly $33.77 billion, with about 2.39 million shares changing hands.

Latest GMAB news

• Genmab Stock Price Shock Puts 3 Oncology Biotech Names In FocusYahoo Finance· Nov 3, 7:10 AM ET
• Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?Yahoo Finance· Oct 29, 7:17 PM ET
• Genmab’s bispecific halves risk of death in first-line HNSCCclinicaltrialsarena.com· Oct 29, 12:24 PM ET
• Genmab soars to record highs after cancer drug succeeds in key trialbiopharmadive.com· Oct 29, 12:06 PM ET
• Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?stocktwits.com· Oct 28, 11:07 PM ET
• Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launchesmarketbeat.com· Oct 28, 5:04 PM ET
• Genmab Stock Surges to Record High After Stunning Cancer Drug ResultsYahoo Finance· Oct 28, 4:19 PM ET
• Genmab Stock Hits 52-Week High - Here's WhyYahoo Finance· Oct 28, 1:44 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want GMAB headlines, alerts and AI research in one place? Create a free account →

• $GMAB $KOD $LZAGF What did I tell you? There’s always a reason behind my picks. 😉📈

  @Stekli27· Nov 3, 11:57 AM ET· Bullish

• $GMAB this will be back in the 40s

  @Itamar1234· Nov 3, 10:12 AM ET· Bearish

• $GMAB Bought 3000 shares of GMAB.

  @Orbit100· Nov 2, 11:19 AM ET· Bullish

• $LLY Added to the top 15 $GMAB Cruised 12 positions up to top 3 $CDNA moved 10 positions up to #1

  @satsandstocks· Nov 1, 11:13 AM ET· Bullish

• Highlights of the week. Some monsters in here, that AIOK div and the FDA approval on INO. Running out of room on this pic. $INO $AIOK $GMAB $GDYN $BOLT to name a few. Before the crowd! Link in bio for more. All trading and investing involves a risk of loss. Do your own due dil…

  @AlertsAndNews· Oct 31, 1:28 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →